, Tracking Stock Market Picks
Enter Symbol:

down 99.79 %

NEUROGESX INC. (NGSX) rated Buy by Wedbush Morgan

Posted on: Friday,  Mar 20, 2009  1:25 PM ET by Wedbush Morgan

Wedbush Morgan rated Buy NEUROGESX INC. (OTCBB: NGSX) on 03/20/2009, when the stock price was $3.10. Since
then, NEUROGESX INC. has lost 99.79% as of 08/27/2015's recent price of $0.01.
If you would have followed this Wedbush Morgan's recommendation on NGSX, you would have lost 99.79% of your investment in 2351 days.

NeurogesX, Inc. (NeurogesX) is a biopharmaceutical company focused on developing and commercializing pain management therapies. The Company is assembling a portfolio of pain management product candidates and is developing new therapies based on known chemical entities. Its initial focus is on the management of chronic peripheral neuropathic pain conditions. The Company?s most advanced product candidate, Qutenza, a dermal patch containing a high concentration of synthetic capsaicin, is designed to manage pain associated with peripheral neuropathic pain conditions. The Company submitted to the United States Food and Drug Administration?s (FDA) an new drug application (NDA) for Qutenza for the management of pain associated with postherpetic neuralgia (PHN), in October 2008 which was filed by the FDA in December 2008. The Company's Products include Qutenza, NGX-1998, Acetaminophen Prodrugs (NGX-1576, NGX-9674, NGX-5752) and Opioid Prodrugs (NGX-6052).

Since 1980, WEDBUSH has used its private equity discipline to invest in under-valued and capital constrained public and private companies that have a significant potential for appreciation. The firm invests with high quality management teams with domain expertise and expects management to retain or make a personally significant equity investment.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
3/20/2009 1:25 PM Buy
as of 12/31/2009
1 Week down  -20.08 %
1 Month down  -25.96 %
3 Months down  -25.87 %
1 YTD up  91.29 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy